Study details
Enrolling now
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
Mohsen Saidinejad
NCT IDNCT07369024ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
120
Study length
about 2 years
Ages
5–20
Locations
1 site in CA
About this study
This trial is testing if a low dose of ketamine helps with pain caused by sickle cell disease. It compares the effects of ketamine plus standard pain medicine to standard pain medicine alone.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Normal Saline Placebo Infusion
- 2.Receive Sub-dissociative Ketamine Infusion
PhasePhase 2
DrugSub-dissociative Ketamine Infusion
Routeinfusion
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low9%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
anesthetic (NMDA receptor antagonist; induces dissociative anesthesia and analgesia)
Drug routes
infusion
Endpoints
Secondary: ED Length of Stay, Pain Score, Quality of Life (Pediatric Quality of Life), Rate of Hospitalization